Stephen T. Zarrilli
Known title: DirectorCIK: 0001203410
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
VRTS Highlighted in Dividend and Analyst Coverage. Virtus Investment Partners appeared in recent financial media discussions focused on high-yield stocks and accurate analyst predictions. The company is noted for a 6.02% dividend yield, which aligns with the theme of the coverage. While the stock is currently trading near its support level, the news primarily centers on its income characteristics rather than a specific corporate event.
Transaction History
| GMED | ▲ Buy | Option Exercise | 25,000 | $1.3M | 8/18/2026 | View on chart |
| GMED | ▼ Sell | Open Market | 25,000 | $2.2M | 8/18/2026 | View on chart |
| GMED | ▲ Buy | Option Exercise | 25,000 | $1.1M | 11/11/2025 | View on chart |
| GMED | ▼ Sell | Open Market | 25,000 | $2.1M | 11/11/2025 | View on chart |
| VRTS | ▼ Sell | Open Market | 2,150 | $534K | 3/6/2024 | View on chart |
| VRTS | ▲ Buy | Grant | 602 | $107K | 5/17/2023 | View on chart |
| VRTS | ▲ Buy | Grant | 585 | $102K | 5/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
RBC Lowers Globus Medical Price Target to $85
RBC Capital has lowered its price target for Globus Medical to $85 while maintaining an Outperform rating. This move comes as the company navigates industry challenges, with recent attention on how medical device firms are using generative AI to manage costs and operations. The stock is currently trading below the average analyst target of $100.92, reflecting a cautious outlook from some investors despite the firm's positive stance.
RBC Lowers Globus Medical Price Target to $85. RBC Capital has lowered its price target for Globus Medical to $85 while maintaining an Outperform rating. This move comes as the company navigates industry challenges, with recent attention on how medical device firms are using generative AI to manage costs and operations. The stock is currently trading below the average analyst target of $100.92, reflecting a cautious outlook from some investors despite the firm's positive stance.